Abstract |
In patients with hematologic malignancies, granulocyte colony-stimulating factor ( G-CSF) following chemotherapy is widely used to mobilize peripheral blood progenitor cells (PBPCs), but there have been no trials comparing schedules of G-CSF following chemotherapy. We conducted a prospective randomized comparative observation of the mobilization with a single dose (10 microg kg once a day) or split dose (5 microg kg twice a day) of lenograstim following chemotherapy in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma (NHL) patients. Chemotherapy was cyclophosphamide 4 g/m2 for MM and ESHAP with or without Rituximab for NHL. The median number of harvested CD34+ cells was 19.4 x 10(6)/kg and 15.8 x 10(6)/kg in the single- and split-dose groups, respectively (p=0.47). Targeted collection of 5 x 10(6) CD34+ cells/kg was achieved in 18/20 patients in the single-dose group and in all 20 patients of the split-dose group (p=0.24), with the median number of sessions 1 and 2 in the single- and split-dose groups, respectively (p=0.13). We could not observe statistically significant differences between a single-dose and split-dose lenograstim following chemotherapy in enhancing the mobilization of PBPCs in MM or NHL patients.
|
Authors | Shin Kim, Hyo-Jung Kim, Jung Sun Park, Jungsin Lee, Hyun-Sook Chi, Chan Jeong Park, Jooryung Huh, Cheolwon Suh |
Journal | Annals of hematology
(Ann Hematol)
Vol. 84
Issue 11
Pg. 742-7
(Oct 2005)
ISSN: 0939-5555 [Print] Germany |
PMID | 16132903
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Lenograstim
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(adverse effects)
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Hematopoietic Stem Cell Mobilization
- Hematopoietic Stem Cells
(physiology)
- Humans
- Lenograstim
- Lymphoma, Non-Hodgkin
(blood, drug therapy)
- Male
- Middle Aged
- Multiple Myeloma
(blood, drug therapy)
- Recombinant Proteins
(therapeutic use)
|